Labcorp and ConcertAI Optimize Precision Oncology Research with Real-World Data and Artificial Intelligence

<span>Labcorp now offers observed collection for COVID-19 PCR testing in over 500 locations nationwide, with plans to Expand to more than 1,000 locations</span>
November 30, 2021

Labcorp now offers observed collection for COVID-19 PCR testing in over 500 locations nationwide, with plans to Expand to more than 1,000 locations

BURLINGTON, N.C. --(BUSINESS WIRE)--Nov. 30, 2021-- Labcorp (NYSE: LH), a global life sciences company, is now offering observed self-collection for COVID-19 PCR testing in more than 500 of its patient service centers (PSCs) nationwide for people without symptoms or known exposure. By mid-December, the company plans to further expand the COVID-19 PCR test collection service to over 1,000 locations.

Labcorp Now Offers Observed Collection for COVID-19 PCR Testing in Over 500 Locations Nationwide, with Plans to Expand to More Than 1,000 Locations

Labcorp to Acquire Toxikon, Expanding Nonclinical Development Testing Capabilities for Pharmaceutical, Biotech and Medical Device Clients

<span>Labcorp to acquire Toxikon, expanding nonclinical development testing capabilities for pharmaceutical, biotech and medical device clients</span>
November 18, 2021

Labcorp to acquire Toxikon, expanding nonclinical development testing capabilities for pharmaceutical, biotech and medical device clients

BURLINGTON, N.C. --(BUSINESS WIRE)--Nov. 18, 2021-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has entered into a definitive agreement to acquire Toxikon, a contract research organization delivering best-in-class nonclinical testing services. Once completed, the transaction will create a strategic footprint for Labcorp to partner with pharmaceutical and biotechnology clients in the Boston, Mass., area and bolster its strong nonclinical development portfolio.